Journal of Artificial Organs

, Volume 20, Issue 3, pp 252–259 | Cite as

Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study

  • Sigrun FrieseckeEmail author
  • Stephanie-Susanne Stecher
  • Stefan Gross
  • Stephan B. Felix
  • Axel Nierhaus
Original Article Others


Sepsis is the most common cause of death in medical intensive care units (ICU). If sepsis progresses to refractory septic shock, mortality may reach 90–100% despite optimum current therapy. Extracorporeal cytokine adsorption in addition to regular therapy was studied prospectively in refractory septic shock patients on a medical ICU. Refractory shock was defined as increasing vasopressor dose required to maintain mean arterial blood pressure above 65 mmHg or increasing lactate levels despite protocol-guided shock therapy for 6 h. We analysed noradrenaline requirements after 6 and 12 h (primary endpoint), lactate clearance after 6 and 12 h, SOFA-scores in the first days and achievement of shock reversal (i.e., normalization of lactate concentrations and sustained discontinuation of vasopressors; secondary endpoints). Twenty consecutive patients with refractory septic shock were included; CytoSorb® treatment was started after 7.8 ± 3.7 h of shock therapy. Following the initiation of adsorption therapy, noradrenaline dose could be significantly reduced after 6 (−0.4 µg/kg/min; p = 0.03) and 12 h (−0.6 µg/kg/min; p = 0.001). Lactate clearance improved significantly. SOFA-scores on day 0, 1 and 2 remained unchanged. Shock reversal was achieved in 13 (65%) patients; 28-day survival was 45%. In severe septic shock unresponsive to standard treatment, haemodynamic stabilization was achieved using cytokine adsorption therapy, resulting in shock reversal in two-thirds of these patients. The study was registered in the German Register for Clinical Trials (DRKS) No. 00005149.


Septic shock therapy Refractory septic shock Interleukin 6 Blood purification CytoSorb® 



We are indebted to the nursing staff of our intensive care unit and the staff of the dialysis department for their excellent work. We thank Mr. Sebastian Maletzki for his help with the data collection and data presentation.

Compliance with ethical standards

Ethics approval and consent to participate

This study was approved by the institutional ethics committee of the Ernst Moritz Arndt University Greifswald (No. BB 048/13). Written informed consent was obtained from patients or their legal representatives.

Conflict of interest

CytoSorbents Europe supplied the hemadsorption cartridges used in this study free of charge. SF has received lecture honoraria, AN has received lecture honoraria and travel reimbursements from CytoSorbents Europe. SSS, SG and SBF declare no conflicts of interest.

Supplementary material

10047_2017_967_MOESM1_ESM.doc (42 kb)
Fig. 3: Interleukin 6 levels before and during treatment with CytoSorb®. Values are shown as mean with 95% CIs in logarithmic scale. Mean and 95%CI values of log-transformed outcomes were accordingly back-transformed to the original scale. Difference vs. “d0” (before CytoSorb® start): ** p < 0.01, *** p < 0.001 (DOC 42 kb)


  1. 1.
    Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606–18.CrossRefPubMedGoogle Scholar
  2. 2.
    Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, et al. Nationwide trends of severe sepsis in the 21st century (2000–2007). Chest. 2011;140:1223–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Parrillo JE. Management of septic shock: present and future. Ann Intern Med. 1991;115:491–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med. 2005;33:2194–201.CrossRefPubMedGoogle Scholar
  5. 5.
    Conrad M, Perez P, Thivilier C, Levy B. Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure. J Crit Care. 2015;30:739–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Benchekroune S, Karpati PC, Berton C, Nathan C, Mateo J, Chaara M, et al. Diastolic arterial blood pressure: a reliable early predictor of survival in human septic shock. J Trauma. 2008;64:1188–95.CrossRefPubMedGoogle Scholar
  7. 7.
    Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine. 2005;29:169–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655–63.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Rimmele T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15:205.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792–801.CrossRefPubMedGoogle Scholar
  12. 12.
    Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008;36:268–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008;36:1573–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA. Cytokine removal with a novel adsorbent polymer. Blood Purif. 2004;22:428–34.CrossRefPubMedGoogle Scholar
  15. 15.
    Schädler D, Porzelius C, Jörres A, Marx G, Meier-Hellmann A, Putensen C, Quintel M, Spies C, Engel C, Weiler N, Kuhlmann M. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. eposter Crit Care; 2013.Google Scholar
  16. 16.
    Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012;81:363–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Mikhova KM, Don CW, Laflamme M, Kellum JA, Mulligan MS, Verrier ED, et al. Effect of cytokine hemoadsorption on brain death-induced ventricular dysfunction in a porcine model. J Thorac Cardiovasc Surgery. 2013;145:215–23 (discussion 23-4).CrossRefGoogle Scholar
  18. 18.
    Hetz H, Berger R, Recknagel P, Steltzer H. Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs. 2014;37:422–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Mitzner SR, Gloger M, Henschel J, Koball S. Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: a case report. Blood Purif. 2013;35:314–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Hinz B, Jauch O, Noky T, Friesecke S, Abel P, Kaiser R. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. Int J Artif Organs. 2015;38:461–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.CrossRefPubMedGoogle Scholar
  22. 22.
    Reiter K, Bordoni V, Dall’Olio G, Ricatti MG, Soli M, Ruperti S, et al. In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif. 2002;20:380–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Bayer O, Reinhart K, Kohl M, Kabisch B, Marshall J, Sakr Y, et al. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med. 2012;40:2543–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–800.CrossRefPubMedGoogle Scholar
  26. 26.
    Haas SA, Lange T, Saugel B, Petzoldt M, Fuhrmann V, Metschke M, et al. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients. Intensive Care Med. 2016;42:202–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Nguyen HB, Loomba M, Yang JJ, Jacobsen G, Shah K, Otero RM, et al. Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. J Inflamm. 2010;7:6.CrossRefGoogle Scholar
  28. 28.
    Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004;32:1637–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Marty P, Roquilly A, Vallee F, Luzi A, Ferre F, Fourcade O, et al. Lactate clearance for death prediction in severe sepsis or septic shock patients during the first 24 hours in Intensive Care Unit: an observational study. Ann Intensive Care. 2013;3:3.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Turnbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE, Coopersmith CM. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock. 2004;21:121–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36:2019–29.CrossRefPubMedGoogle Scholar
  32. 32.
    Shiga H, Hirasawa H, Nishida O, Oda S, Nakamura M, Mashiko K, et al. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: a preliminary report. Blood Purif. 2014;38:211–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Peng Z, Singbartl K, Simon P, Rimmele T, Bishop J, Clermont G, et al. Blood purification in sepsis: a new paradigm. Contrib Nephrol. 2010;165:322–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Peng ZY, Bishop JV, Wen XY, Elder MM, Zhou F, Chuasuwan A, et al. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model. Crit Care. 2014;18:R141.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bello G, Di Muzio F, Maviglia R, Antonelli M. New membranes for extracorporeal blood purification in septic conditions. Minerva Anestesiol. 2012;78:1265–81.PubMedGoogle Scholar
  36. 36.
    Venkataraman R, Subramanian S, Kellum JA. Clinical review: extracorporeal blood purification in severe sepsis. Crit Care. 2003;7:139–45.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41:2209–20.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Antonelli M, Cutuli SL, Ronco C. Polymyxin B hemoperfusion in septic shock: just look at the evidence! Intensive Care Med. 2015;41:1731–2.CrossRefPubMedGoogle Scholar
  39. 39.
    Trager K, Fritzler D, Fischer G, Schroder J, Skrabal C, Liebold A, et al. Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. Int J Artif Organs. 2016;39:141–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Cornejo R, Downey P, Castro R, Romero C, Regueira T, Vega J, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med. 2006;32:713–22.CrossRefPubMedGoogle Scholar
  41. 41.
    Vieillard-Baron A, Caille V, Charron C, Belliard G, Aegerter P, Page B, et al. Reversal of refractory septic shock with drotrecogin alpha (activated). Intensive Care Med. 2009;35:1204–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Donati A, Domizi R, Damiani E, Adrario E, Pelaia P, Ince C. From macrohemodynamic to the microcirculation. Crit Care Res Pract. 2013;2013:892710.PubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society for Artificial Organs 2017

Authors and Affiliations

  • Sigrun Friesecke
    • 1
    Email author
  • Stephanie-Susanne Stecher
    • 1
  • Stefan Gross
    • 2
  • Stephan B. Felix
    • 1
    • 2
  • Axel Nierhaus
    • 3
  1. 1.Department of Internal Medicine B (Cardiology, Pneumology, Medical Intensive Care Medicine)University Medical Center GreifswaldGreifswaldGermany
  2. 2.DZHK-German Centre for Cardiovascular Research, Partner Site GreifswaldGreifswaldGermany
  3. 3.Department of Intensive Care MedicineUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations